| Patients with inflammatory bowel disease and their treating clinicians have different views regarding diet DQ Holt, BJ Strauss, GT Moore Journal of Human Nutrition and Dietetics 30 (1), 66-72, 2017 | 112 | 2017 |
| Visceral adiposity predicts post‐operative Crohn's disease recurrence DQ Holt, GT Moore, BJG Strauss, AL Hamilton, P De Cruz, MA Kamm Alimentary pharmacology & therapeutics 45 (9), 1255-1264, 2017 | 103 | 2017 |
| Body composition analysis using abdominal scans from routine clinical care in patients with Crohn’s Disease DQ Holt, BJG Strauss, KK Lau, GT Moore Scandinavian Journal of Gastroenterology 51 (7), 842-847, 2016 | 45 | 2016 |
| Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis DQ Holt, P Varma, BJG Strauss, AS Rajadurai, GT Moore European journal of clinical nutrition 71 (6), 773-777, 2017 | 43 | 2017 |
| Marantic endocarditis presenting as recurrent arterial embolisation SB Joshi, MJ Richards, DQ Holt, BP Yan, A Aggarwal International journal of cardiology 132 (1), e14-e16, 2009 | 24 | 2009 |
| The role of body composition in diverticular disease J Freckelton, D Holt, A Borsaru, SM Gwini, D Croagh, G Moore International journal of colorectal disease 33, 1299-1302, 2018 | 15 | 2018 |
| Clinical selection criteria can predict futile intervention in patients referred for percutaneous endoscopic gastrostomy insertion DQ Holt, JF McDonald, ML Murray, C Hair, DA Devonshire, BJ Strauss, ... Internal Medicine Journal 45 (6), 648-652, 2015 | 10 | 2015 |
| Body composition adjusted dosing of Gemcitabine-Nab-Paclitaxel in pancreatic cancer does not predict toxicity compared to body surface area dosing J Freckelton, D Croagh, DQ Holt, A Fox, R Wong, M Lee, GT Moore Nutrition and cancer 71 (4), 624-628, 2019 | 9 | 2019 |
| Weight and body composition compartments do not predict therapeutic thiopurine metabolite levels in inflammatory bowel disease DQ Holt, BJG Strauss, GT Moore Clinical and Translational Gastroenterology 7 (10), e199, 2016 | 7 | 2016 |
| Immunomodulator use does not prevent first loss of response to anti-TNF therapy in inflammatory bowel disease: long term outcomes in a real-world cohort P Varma, AS Rajadurai, DQ Holt, DA Devonshire, CP Desmond, ... Intern Med J 49, 753-760, 2019 | 6 | 2019 |
| Non-alcoholic fatty liver disease Intermittent Fasting Time Intervention (NIFTI): Fasting without calorie restriction improves hepatic transient elastography, visceral … A Hodge, A Mack, C Tuck, J Tchongue, DQ Holt, W Sievert, GT Moore Hepatology 60, 632A, 2014 | 6 | 2014 |
| Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point‐of‐care measurements of skeletal muscle mass in patients with inflammatory bowel disease AL Nguyen, M Burns, M Herath, K Lambell, D Holt, J Fitzpatrick, F Milat, ... Alimentary Pharmacology & Therapeutics 58 (3), 309-321, 2023 | 3 | 2023 |
| Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease—A Single Blinded Crossover Trial J Feehan, A Mack, C Tuck, J Tchongue, DQ Holt, W Sievert, GT Moore, ... Nutrients 15 (23), 4870, 2023 | 2 | 2023 |
| Parenteral nutrition in adults during acute illness: a clinical perspective for clinicians K Fetterplace, D Holt, A Udy, E Ridley Internal Medicine Journal 50 (4), 403-411, 2020 | 2 | 2020 |
| The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study AL Nguyen, M Herath, M Burns, D Holt, PR Ebeling, F Milat, PR Gibson, ... European Journal of Gastroenterology & Hepatology 36 (1), 52-61, 2024 | 1 | 2024 |
| Immunomodulator use does not prevent first loss of response to anti‐tumour necrosis factor alpha therapy in inflammatory bowel disease: long‐term outcomes in a real‐world cohort P Varma, AS Rajadurai, DQ Holt, DA Devonshire, CP Desmond, ... Internal Medicine Journal 49 (6), 753-760, 2019 | 1 | 2019 |
| Low muscle mass at treatment initiation is associated with early loss of response to anti-TNF therapy for Inflammatory Bowel Disease D Holt, P Varma, B Strauss, G Moore JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30, 131-131, 2015 | 1 | 2015 |
| Do Tenofovir and Entecavir affect renal function in patients with chronic hepatitis B (CHB)? A two-year observational study from a single Australian centre P Ha, T He, J Lim, L Sahhar, S Le, F Rusli, DQ Holt, D Ratnam, S Pianko, ... Journal of gastroenterology and hepatology 27, 77-78, 2012 | 1 | 2012 |
| Colonic cytomegalovirus DNA detection by polymerase chain reaction does not influence outcomes in inflammatory bowel disease and immunosuppressed cohorts P Nguyen, A Shrestha, N Sane, D Abeywickrama, DQ Holt, S Bell, ... Internal Medicine Journal 54 (2), 283-289, 2024 | | 2024 |
| P274 Bioelectrical impedance analysis identifies low skeletal muscle index in patients with Inflammatory Bowel Disease A Nguyen, D Holt, M Burns, M Herath, PR Gibson, P Ebeling, F Milat, ... Journal of Crohn's and Colitis 16 (Supplement_1), i311-i311, 2022 | | 2022 |
